Frequently Asked Questions
The market is segmented based on By Type (Motor Tics and Vocal Tics), Product Type (Antipsychotics and Non-antipsychotics), Diagnosis (Blood Diagnosis, Imaging Diagnosis, and Others), Drug type (Fluphenazine, Haloperidol, Risperidone, Pimozide, Tetrabenazine, Botulinum (Botox) Injections, Methylphenidate, Dextroamphetamine, Clonidine, Guanfacine, and Fluoxetine), Therapy Type (Behavior Therapy, Psychotherapy, Deep Brain Stimulation (DBS), Comprehensive Behavioral Intervention for Tics (CBIT), and Others), End-User (Hospitals, Clinics, and Others) - Industry Trends and Forecast to 2030.
.
The Global Tourette Syndrome Market size was valued at USD 2501.00 USD Million in 2022.
The Global Tourette Syndrome Market is projected to grow at a CAGR of 4.2% during the forecast period of 2023 to 2030.
The major players operating in the market include Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Pfizer , Otsuka Holdings Co Ltd, Mylan N.V, Johnson & Johnson Services , H Lundbeck A/S, Eli Lilly and Company, Boehringer Ingelheim International GmbH, AstraZeneca, Catalyst Pharma, Neurocrine Biosciences , Reviva Pharmaceuticals , Therapix Biosciences Ltd, Emalex Biosciences , Beijing PINS Medical Co Ltd, FGK Clinical Research GmbH, Medtronic, Bausch Health Companies .
The market report covers data from the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
